Destinations Multi Strategy Alternatives Fund
Destinations Multi Strategy Alternatives Fund reported 28 holdings worth US$532M as of Feb 28, 2026 (Form N-PORT)
As of Feb 28, 2026 · Filed Apr 28, 2026
Destinations Multi Strategy Alternatives Fund reported 28 holdings worth US$532M as of Feb 28, 2026. Largest: Xenon Pharmaceuticals Inc., Hillman Solutions Corp. and K&f Growth Acquisition Corp. Ii. Filed Apr 28, 2026 (Form N-PORT).
- Holdings
- 28
- Value as reported
- US$532M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Xenon Pharmaceuticals Inc. | 206K | US$8.89M | 1.7% |
| Hillman Solutions Corp. | 658K | US$5.4M | 1.0% |
| K&f Growth Acquisition Corp. Ii | 512K | US$5.32M | 1.0% |
| Oaktree Acquisition Corp. Iii Life Sciences | 480K | US$5.07M | 0.95% |
| Jefferson Capital, Inc. | 243K | US$5.01M | 0.94% |
| Bold Eagle Acquisition Corp. | 474K | US$4.99M | 0.94% |
| Willscot Holdings Corporation | 227K | US$4.91M | 0.92% |
| Gxo Logistics, Inc. | 72,946 | US$4.58M | 0.86% |
| Archimedes Tech Spac Partners Ii Co. | 406K | US$4.28M | 0.80% |
| Cannae Holdings, Inc. | 291K | US$3.55M | 0.67% |
| Highview Merger Corp. | 333K | US$3.35M | 0.63% |
| Newhold Investment Corp Iii | 265K | US$2.76M | 0.52% |
| Penn Entertainment, Inc. | 162K | US$2.53M | 0.48% |
| Willow Lane Acquisition Corp. | 222K | US$2.37M | 0.45% |
| Gesher Acquisition Corp. Ii | 213K | US$2.21M | 0.42% |
| Dynamix Corporation Iii | 210K | US$2.08M | 0.39% |
| Apex Treasury Corporation | 175K | US$1.73M | 0.33% |
| Porch Group, Inc. | 205K | US$1.69M | 0.32% |
| Galata Acquisition Corp. Ii | 139K | US$1.39M | 0.26% |
| Btc Development Corp. | 70,586 | US$708K | 0.13% |
| Cantor Equity Partners Iii, Inc. | 63,886 | US$655K | 0.12% |
| Crinetics Pharmaceuticals, Inc. | 15,416 | US$634K | 0.12% |
| Septerna, Inc. | 14,085 | US$409K | 0.08% |
| Cantor Equity Partners V, Inc. | 35,001 | US$355K | 0.07% |
| Insight Digital Partners Ii | 34,952 | US$347K | 0.07% |
| Hcm Iii Acquisition Corp. | 33,162 | US$336K | 0.06% |
| Viridian Therapeutics, Inc. | 7,098 | US$209K | 0.04% |
| Apogee Therapeutics, Inc. | 2,200 | US$154K | 0.03% |
Source
View original at SEC
Related